Genomic Test Result Interpretation Note

**Genomic Test Result Interpretation Note** **Test Details:** The test performed was a Next-Generation Sequencing (NGS) panel targeting 150 genes associated with hereditary cancer syndromes. The test was conducted by Genomics Lab on 1 November 2024, using a blood sample. Quality metrics indicated a 99% coverage at 20x depth. Reference number: G123456789. **Indication for Testing:** The genetic test was indicated due to a family history of breast and ovarian cancer, with the patient presenting with early-onset breast cancer. The test aimed to identify potential hereditary cancer predisposition variants. **Summary of Results:** The test identified a pathogenic variant in the BRCA1 gene (c.68_69delAG, p.Glu23Valfs*17) located on chromosome 17. The variant is classified as pathogenic according to ACMG guidelines and is diagnostic for hereditary breast and ovarian cancer syndrome. **Interpretation:** The BRCA1 variant detected is known to be associated with a significantly increased risk of breast and ovarian cancer. The patient's family history and early-onset breast cancer phenotype support the clinical significance of this finding. The variant's pathogenicity is well-documented in the literature. **Secondary/Incidental Findings:** No actionable secondary findings were identified in this test. **Variant of Uncertain Significance:** A VUS was detected in the ATM gene (c.7271T>G, p.Val2424Gly). Current literature and database annotations provide conflicting evidence regarding its clinical significance. Reclassification efforts are recommended as new data becomes available. **Limitations of Testing:** The test may not detect deep intronic variants or large structural rearrangements. Low coverage areas may exist, and not all gene-disease links are fully validated. **Recommendations:** Referral to a specialist in hereditary cancer syndromes is advised. Family cascade testing for the BRCA1 variant is recommended. Enhanced surveillance and management guidelines for breast and ovarian cancer should be discussed. **Counselling Provided:** Genetic counselling was provided to discuss the implications of the BRCA1 variant, including risk communication and family planning options. The patient was supported in informed decision-making regarding surveillance and preventive measures.